From May 16 to 18, 2025, the Zhejiang Medical Association Andrology Academic Conference and the 15th South Taihu Urology and Minimally Invasive Technology Academic Conference were grandly launched in Huzhou. The event brought together numerous experts, scholars, and industry elites in the field of andrology, shining a light on the future of andrology medicine. WBL Medical Group was invited to exhibit and, with its cutting-edge achievements and outstanding presence, became the focal point of the conference.

Founded in 1932, the Zhejiang Medical Association is an academic, public welfare, and non-profit organization formed by voluntary medical science and technology workers in the province. With a long history and wide influence, it promotes academic exchanges, services to members, talent development, and more. Under the guidance of various departments, it has built service platforms and various specialized divisions. The association currently has over 20,000 registered members and 100 specialist sub-associations, and it has received numerous honors, including “National Advanced Social Organization.”

Focus on the Exhibition: WBL’s Booth Attracts Attention

At the exhibition, WBL Medical Group's booth attracted much attention. Its core product, the low-energy pulsed ultrasound therapy device (LIPUS) — the A-version small cabin, made a stunning debut. The product integrates cutting-edge technology with user-friendly design, featuring a unique appearance and outstanding performance, quickly becoming the focal point of the attendees. Many participants engaged in detailed discussions with staff about the product's technical principles, clinical application results, and other aspects, creating a lively and active atmosphere.

Innovative Breakthrough: Lü Bodong's Team Introduces a New Therapy

During the academic exchange session, Lü Bodong, the director of Zhejiang Chinese Medical University Second Affiliated Hospital, shared his team’s latest research findings. They innovatively proposed a new treatment plan combining WBL LIPUS with tadalafil for mild to moderate erectile dysfunction, opening a new path for the treatment of andrological diseases. Lü elaborated on the effects and mechanisms of low-intensity pulsed ultrasound therapy, helping attendees gain a comprehensive and deep understanding of this cutting-edge technology. Research data indicated that the combined therapy is highly effective, bringing new hope to patients.

In-Depth Interpretation: Dr. Xu Zhipeng Shares Research Findings

Following this, Dr. Xu Zhipeng gave an insightful presentation. He explained in a clear and accessible manner the effects and mechanisms of LIPUS low-intensity pulsed ultrasound therapy, allowing the attendees to gain a more thorough understanding of this advanced technology. Dr. Xu also provided detailed information on the product features, advantages, and clinical application cases of WBL LIPUS — A version small cabin. Through his presentation, the attendees clearly recognized that WBL LIPUS — A version small cabin is not only technologically advanced but also provides a safer, more effective, and more convenient treatment experience for patients in practical applications.

Dr. Xu Zhipeng

Deputy Chief Physician of Andrology at Nanjing Drum Tower Hospital

Member of the Andrology Branch of Nanjing Medical Association

Member of the Andrology Group of Urology Branch of Jiangsu Medical Association

Member of the Family Planning and Reproductive Medicine Branch of Nanjing Medical Association

WBL LIPUS Technology and Development

WBL Medical Group, as the pioneer of LIPUS technology, has independently developed the LIPUS - ED device, which was the first to apply low-intensity pulsed ultrasound technology to treat erectile dysfunction, providing a non-invasive, safe, and effective solution. This device was approved for sale by CFDA in 2018, filling a technological gap domestically and internationally, and it won the China National Medical Device Innovation Award. The core mechanism is to use ultrasound waves within a specific intensity range to activate endogenous stem cells, promoting vascular and nerve regeneration to improve erectile function at the pathological level, without relying on drugs or surgery, thus avoiding the side effects and inconveniences of traditional therapies.

Participating in the Huzhou exhibition was not only an opportunity for WBL Medical Group to showcase its strength and products but also a valuable chance for in-depth exchanges and learning with industry experts and peers. Through interactions with various individuals, WBL Medical further understood market demands and industry development trends, laying a solid foundation for future product research and market expansion.